# Wharton Asset Management Company Limited

> Wharton Asset Management Company Limited is a VC fund backing Health Care. See 7 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: London, United Kingdom
- Total investments: 7
- Last investment: Aug 2025
- Lead investor: 43%
- Last updated: Aug 2026

Wharton Asset Management Company Limited is a VC fund in London focused on Health Care and Medical. Wharton Asset Management is an investment management company.

## Contacts

5 contacts available for Wharton Asset Management Company Limited. Shizune tracks 1 team members at Wharton Asset Management Company Limited. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/wharton-asset-management-company-limited?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $1.9M–$6.5M |
| Venture - Series Unknown | $6.7M–$12M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 29% |
| Medical | 1 | 14% |
| Security | 1 | 14% |
| Software | 1 | 14% |
| Wellness | 1 | 14% |

10 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 29% |
| Venture - Series Unknown | 2 | 29% |
| Seed | 1 | 14% |
| Funding Round | 1 | 14% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Gaby Salem | Managing Director | 3 | https://shizune.co/investors/profile/gaby-salem |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Neurovalens | Neurovalens delivers innovative solutions in the field of neuroscience, bioscience and neurophysiology.Neurovalens has received support from Invest NI under the European Union’s Investment for Growth and Jobs Programme. The project, recorded on the ERDF beneficiaries’ website, will be implemented over the next one year, undertaking research anddevelopment activities aimed at improving the competitiveness of the business. | $6.7M | Venture - Series Unknown | Aug 19, 2025 |  |
| B-Secur | B-Secur are on a mission to revolutionise the way people experience technology in the connected world using their unique heartbeat. We’ve invested over 15 years of deep, scientific research in ECG to become a world leader in the development and integration of ECG technology, partnering with some of the world's leading technology companies.We’ve harnessed the power of ECG to create HeartKey®, offering advanced physiological monitoring with intrinsic data protection.We have developed a suite of powerful ECG algorithms and analytics for user identification, wellness, and health, ready for integration into leading devices and systems. B-Secur also have a combined 50+ years of in-house hardware and material science, which our partners can use to significantly reduce development costs on hardware and ECG electrode design. B-Secur and HeartKey® bring you our world class expertise in ECG combined with powerful, flexible integration and configuration possibilities to create your optimal product, with a competitive edge. | $11.9M | Venture - Series Unknown | Nov 04, 2021 |  |
| B-Secur | B-Secur are on a mission to revolutionise the way people experience technology in the connected world using their unique heartbeat. We’ve invested over 15 years of deep, scientific research in ECG to become a world leader in the development and integration of ECG technology, partnering with some of the world's leading technology companies.We’ve harnessed the power of ECG to create HeartKey®, offering advanced physiological monitoring with intrinsic data protection.We have developed a suite of powerful ECG algorithms and analytics for user identification, wellness, and health, ready for integration into leading devices and systems. B-Secur also have a combined 50+ years of in-house hardware and material science, which our partners can use to significantly reduce development costs on hardware and ECG electrode design. B-Secur and HeartKey® bring you our world class expertise in ECG combined with powerful, flexible integration and configuration possibilities to create your optimal product, with a competitive edge. | $1.9M | Series A | Sep 15, 2020 |  |
| Neurovalens | Neurovalens delivers innovative solutions in the field of neuroscience, bioscience and neurophysiology.Neurovalens has received support from Invest NI under the European Union’s Investment for Growth and Jobs Programme. The project, recorded on the ERDF beneficiaries’ website, will be implemented over the next one year, undertaking research anddevelopment activities aimed at improving the competitiveness of the business. |  |  | Jul 20, 2020 |  |
| Neurovalens | Neurovalens delivers innovative solutions in the field of neuroscience, bioscience and neurophysiology.Neurovalens has received support from Invest NI under the European Union’s Investment for Growth and Jobs Programme. The project, recorded on the ERDF beneficiaries’ website, will be implemented over the next one year, undertaking research anddevelopment activities aimed at improving the competitiveness of the business. | $6.5M | Series A | Jul 20, 2020 |  |
| B-Secur | B-Secur are on a mission to revolutionise the way people experience technology in the connected world using their unique heartbeat. We’ve invested over 15 years of deep, scientific research in ECG to become a world leader in the development and integration of ECG technology, partnering with some of the world's leading technology companies.We’ve harnessed the power of ECG to create HeartKey®, offering advanced physiological monitoring with intrinsic data protection.We have developed a suite of powerful ECG algorithms and analytics for user identification, wellness, and health, ready for integration into leading devices and systems. B-Secur also have a combined 50+ years of in-house hardware and material science, which our partners can use to significantly reduce development costs on hardware and ECG electrode design. B-Secur and HeartKey® bring you our world class expertise in ECG combined with powerful, flexible integration and configuration possibilities to create your optimal product, with a competitive edge. | $5.2M | Series A | Mar 05, 2019 |  |
| B-Secur | B-Secur are on a mission to revolutionise the way people experience technology in the connected world using their unique heartbeat. We’ve invested over 15 years of deep, scientific research in ECG to become a world leader in the development and integration of ECG technology, partnering with some of the world's leading technology companies.We’ve harnessed the power of ECG to create HeartKey®, offering advanced physiological monitoring with intrinsic data protection.We have developed a suite of powerful ECG algorithms and analytics for user identification, wellness, and health, ready for integration into leading devices and systems. B-Secur also have a combined 50+ years of in-house hardware and material science, which our partners can use to significantly reduce development costs on hardware and ECG electrode design. B-Secur and HeartKey® bring you our world class expertise in ECG combined with powerful, flexible integration and configuration possibilities to create your optimal product, with a competitive edge. | $4.6M | Seed | Jul 25, 2017 |  |

7 of 7 investments shown.

## Co-investors
- [Kernel Capital](https://shizune.co/investors/profile/kernel-capital-partners) — VC Fund, 5 deals together
- [Clarendon Fund Managers](https://shizune.co/investors/profile/clarendon-fund-managers) — VC Fund, 4 deals together
- [ADV](https://shizune.co/investors/profile/accelerated-digital-ventures) — VC Fund, 3 deals together
- [ACF Investors](https://shizune.co/investors/profile/angel-cofund) — VC Fund, 3 deals together
- [IQ Capital](https://shizune.co/investors/profile/iq-capital-partners) — VC Fund, 3 deals together
- [Techstart Ventures](https://shizune.co/investors/profile/techstart-ventures) — VC Fund, 3 deals together

## Similar investors

### Similar industry
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Gaingels](https://shizune.co/investors/profile/gaing) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [Fuel Ventures](https://shizune.co/investors/profile/fuel-ventures-fund) — VC Fund
- [Business Growth Fund](https://shizune.co/investors/profile/business-growth-fund) — VC Fund

## Featured in investor lists
- [Wellness Investors in United Kingdom](https://shizune.co/investors/wellness-investors-united-kingdom)

## FAQ

### What does Wharton Asset Management Company Limited invest in?

Wharton Asset Management Company Limited invests primarily in Health Care, Medical and Security startups, most often at Series A and Venture - Series Unknown stage. Most of the 7 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Wharton Asset Management Company Limited's check size?

Wharton Asset Management Company Limited typically joins rounds of $1.9M–$6.5M at Series A and $6.7M–$12M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Wharton Asset Management Company Limited participates in.

### How do I contact Wharton Asset Management Company Limited?

For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Wharton Asset Management Company Limited?

The team at Wharton Asset Management Company Limited includes Gaby Salem (Managing Director). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co